The Biovac
Institute is a Public-Private Partnership (PPP) between
the Biovac Consortium and the Department of Health,
incorporating the State Vaccine Institute into a
commercial company. Biovac aims to revitalize vaccine
manufacturing in South Africa by build capacity in all
aspects of vaccine development and manufacture, from
products for clinical trials to full scale commercial
production, for both local and international markets.
Product Offering:
The Biovac
Institute has various product and service offerings
within the vaccine development and manufacturing value
chain:
New Product Development - Biovac
is currently developing combination vaccines to
build value within the Institute and supply the
African market with pentavalent vaccines. The
multi-valent drug, comprising vaccines for
Diphtheria, Pertussis, Tetanus (DTP), hepatitis B
and Haemophilus Influenza B (HIB), will not only
improve health prospects on the continent, but
will also ensure the Institute manufactures a
profitable biotech drug.
Manufacturing - Biovac has
established bulk filling and formulating
capabilities and has recently completed
construction and validation of a medical
warehousing and packaging facility.
Sales and Distribution - Biovac
imports, packages and distributes vaccines to the
private and public healthcare sector in southern
Africa and has been doing so successfully over the
passed 15 years.
All funding will be used to
position the Biovac Institute as an international
vaccine manufacturer which develops and
distributes relevant vaccines to the market. This
involves building new and upgrading existing
facilities, purchasing new equipment and employing
additional skilled professionals to increase
capabilities and drive competitive
advantage.
Technology :
Biovac employs a number of existing
technologies in the development and manufacture of vaccines:
Combination Technology - a method
of combining vaccines for different illnesses into
one, while maintaining safety and efficacy of all
the vaccine components.
Profile:
The
Department of Health, Cape Biotech Trust and the Biovac
Consortium, are shareholders of the Biovac Institute.
The Institute is supported by the Cape Biotech Trust, an
initiative of the Department of Science and
Technology
Address
The Biovac Institute, 15,
Alexandra Road, Pinelands,
Cape Town, South Africa
Telephone : +27 21 511 2266
Fax : +27 21 511 3962
Disclaimer
: By accessing the DCVMN site, a user agrees not to redistribute the
information found there in.
